Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rein Therapeutics ( (RNTX) ) has shared an announcement.
On June 10, 2025, Rein Therapeutics paused enrollment and patient dosing in the U.S. for its Phase 2 RENEW trial of LTI-03 due to a clinical hold by the FDA, while continuing the trial in Australia, the UK, and Europe. The company is addressing FDA requests to resume U.S. activities, and no drug-related serious adverse events have been reported, highlighting the drug’s safety profile.
The most recent analyst rating on (RNTX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Rein Therapeutics stock, see the RNTX Stock Forecast page.
Spark’s Take on RNTX Stock
According to Spark, TipRanks’ AI Analyst, RNTX is a Underperform.
Rein Therapeutics is experiencing severe financial difficulties, with persistent negative net income and cash flows. The technical analysis suggests bearish momentum with potential near-term volatility. The negative P/E ratio and lack of dividends further highlight the company’s weak financial position. The overall outlook for the stock is challenging, with significant risks outweighing potential rewards.
To see Spark’s full report on RNTX stock, click here.
More about Rein Therapeutics
Rein Therapeutics, Inc. operates in the biotechnology industry, focusing on developing treatments for idiopathic pulmonary fibrosis (IPF). Its primary product, LTI-03, is a novel, multi-pathway, Caveolin-1-related peptide designed for IPF treatment.
Average Trading Volume: 34,725
Technical Sentiment Signal: Sell
Current Market Cap: $42.98M
See more data about RNTX stock on TipRanks’ Stock Analysis page.